Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization

Purpose: to identify statistically significant factors that determine adherence to long-term follow-up on the part of patients receiving anti-VEGF therapy for macular diseases.Material and methods. A retrospective analysis was performed on 247 patients (153 women, 94 men) aged 24 to 92 years treated with anti-VEGF for “wet” age-related macular degeneration (n = 164), diabetic macular edema (n = 18), macular edema due to retinal vein occlusion (n = 35) and myopic choroidal neovascularization (n = 30). Demographic data and treatment results were statistically analyzed with the STATISTICA 13.3 program (normal conditions for variables, non-parametric and parametric criteria were determined).Results. Follow-up duration was shown to depend on gender (women are more committed to long-term treatment, p < 0.05), diagnosis (the longest follow-up related to myopic choroidal neovascularization patients), initial and final visual acuity. The comparison of subgroups of patients with the longest (over 30 months, n = 56) and shortest (till 12 months, n = 92) follow-up showed that prolonged monitoring corresponds to higher values of the initial (p < 0.01) and final (p < 0.05) visual acuity, as well as a lower average number of injections over the entire follow-up (p < 0.001) and a younger age of patients (p = 0.02).Conclusion. The follow-up duration depends on gender and age, the intensity of treatment, as well as on the initial and final visual acuity at a significance level of ˂ 0.05. Also, the follow-up duration depends on the particular diagnosis. An indicator clearly reflecting the severity of the burden of treatment is proposed: the coefficient of therapy intensity which is inversely related to the patient’s adherence to therapy.

Download Full-text

Anti-VEGF Therapy in Myopic Choroidal Neovascularization: Long-Term Results

Ophthalmologica ◽

10.1159/000360307 ◽

2014 ◽

Vol 232 (1) ◽

pp. 57-63 ◽

Cited By ~ 13

Author(s):

Paulo Freitas-da-Costa ◽

João Pinheiro-Costa ◽

Beatriz Carvalho ◽

Manuel Falcão ◽

Elisete Brandão ◽

...

Keyword(s):

Choroidal Neovascularization ◽

Long Term Results ◽

Myopic Choroidal Neovascularization ◽

Anti Vegf

Download Full-text

Long term effect of repeated hyperbaric oxygen therapy on visual acuity in inflammatory cystoid macular oedema

British Journal of Ophthalmology ◽

10.1136/bjo.81.4.329 ◽

1997 ◽

Vol 81 (4) ◽

pp. 329-329 ◽

Cited By ~ 9

Author(s):

M S A SUTTORP-SCHULTEN ◽

F C C RIEMSLAG ◽

A ROTHOVA ◽

A J VAN DER KLEY ◽

F C C RIEMSLAG

Keyword(s):

Visual Acuity ◽

Hyperbaric Oxygen ◽

Macular Oedema ◽

Hyperbaric Oxygen Therapy ◽

Oxygen Therapy ◽

Term Effect ◽

Cystoid Macular Oedema ◽

Long Term Effect

Download Full-text

Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica

Acta Médica Portuguesa ◽

10.20344/amp.2038 ◽

2014 ◽

Vol 27 (1) ◽

pp. 49 ◽

Cited By ~ 1

Author(s):

Beatriz Carvalho ◽

Paulo Freitas-Costa ◽

João Pinheiro-Costa ◽

Manuel Falcão ◽

Ângela Carneiro ◽

...

Keyword(s):

Visual Acuity ◽

Choroidal Neovascularization ◽

Vision Loss ◽

Long Term Results ◽

Myopic Choroidal Neovascularization ◽

Corrected Visual Acuity ◽

Foveal Center ◽

Best Corrected Visual Acuity

Introduction: Choroidal neovascularization secondary to pathological myopia is one of the leading causes of irreversible central vision loss in younger patients. The purposes of our study is to evaluate the long-term results of antiangiogenic treatment, with ranibizumab and/or bevacizumab, in myopic choroidal neovascularization and define the predictive factors for visual and anatomic outcomes. Material and Methods: In this study were included 84 eyes from 81 patients with myopic choroidal neovascularization. Eighty-four (100%) eyes accomplish 12 months of follow-up, 67 (79.8%) 24 months, 54 (64.3%) 36 months, 29 (34.5%) 48 months, and 15 (16.7%) 60 months. We retrieved data related to best corrected visual acuity measured with ETDRS chart, foveal center thickness on optical coherence tomography and fluorescein angiographic findings, before and after treatment. Results: The best corrected visual acuity and foveal center thickness improvements were statistically significant for all follow-up times (p < 0.05). Mean baseline best corrected visual acuity was 43.7 ± 20.1 letters and mean baseline foveal center thickness was 304.8 ± 127.9μm. Mean best corrected visual acuity was 55.6 ± 18.5, 52.1 ± 22.3, 52.1 ± 22.6, 50.3 ± 23.8 and 47.8 ± 24.5 for 12, 24, 36, 48 and 60 months of treatment, respectively. Mean foveal center thickness was 209.7 ± 86.2, 190.6 ± 76.1, 174.7 ± 60.6, 189.8 ± 96.7 and 159.4 ± 73.3 for the same follow-up times. Baseline best corrected visual acuity was the only predictive factor for better visual outcome (p < 0.001). Discussion/Conclusion: Intravitreal anti-VEGF injections in patients with myopic choroidal neovascularization yielded a significant and sustained functional and anatomic improvement. Randomized long-term clinical trials are needed to determine the sustained efficacy of these drugs.

Download Full-text

The Long-term Effect of Vitreous Presentation During Extracapsular Cataract Surgery on Postoperative Visual Acuity

American Journal of Ophthalmology ◽

10.1016/j.ajo.2007.05.021 ◽

2007 ◽

Vol 144 (2) ◽

pp. 286-287 ◽

Cited By ~ 1

Author(s):

Shaleen L. Belani ◽

Samuel Masket

Keyword(s):

Visual Acuity ◽

Cataract Surgery ◽

Term Effect ◽

Postoperative Visual Acuity ◽

Long Term Effect ◽

Extracapsular Cataract Surgery

Download Full-text

Anti-VEGF-Therapie bei myopischer choroidaler Neovaskularisation: Langzeitergebnisse

Karger Kompass Ophthalmologie ◽

10.1159/000370022 ◽

2015 ◽

Vol 1 (1) ◽

pp. 38-39

Keyword(s):

Visual Acuity ◽

Choroidal Neovascularization ◽

Retinal Thickness ◽

Central Retinal Thickness ◽

Myopic Choroidal Neovascularization ◽

Retrospektive Analyse ◽

Corrected Visual Acuity ◽

Anti Vegf ◽

Best Corrected Visual Acuity

Ziel: Beurteilung der mittel- und langfristigen Wirksamkeit von Anti-VEGF-Wirkstoffen in der Behandlung der choroidalen Neovaskularisation infolge einer pathologischen Myopie (myopic choroidal neovascularization; mCNV).Methoden: Retrospektive Analyse von mCNV-Patienten, die 2 Jahre oder länger mit einer intravitrealen Anti-VEGF-Therapie behandelt worden waren. Wir verglichen die Sehschärfe mit bester Korrektur (best-corrected visual acuity; BCVA) sowie die zentrale Netzhaut-Dicke (central retinal thickness; CRT) vor und nach der Behandlung. Die Anzahl der Injektionen pro Jahr wurde ebenfalls erfasst.Ergebnisse: Auswertungen der Ergebnisse erfolgten nach 2 Jahren für 67 Augen, nach 3 Jahren für 52 Augen, nach 4 Jahren für 28 Augen und nach 5 Jahren für 13 Augen. Die mittlere Veränderung der BCVA gegenüber dem Ausgangswert war nach 2 Jahren signifikant (+8,6 Buchstaben; p < 0,001); diese Verbesserung blieb über einen Zeitraum von 5 Jahren signifikant stabil bestehen. Die mittlere CRT nahm im Verlauf signifikant ab; der Tiefstwert war nach 2 Jahren erreicht (-104,0 μm; p < 0,001). Die mittlere Anzahl der Injektionen betrug im 1. Jahr 5,2 und ging in den nachfolgenden Jahren zurück (p < 0,001).Schlussfolgerung: In der hier beschriebenen Untergruppe von mCNV-Patienten war die intravitreale Anti-VEGF-Therapie über einen Zeitraum von 5 Jahren wirksam, wobei sich der BCVA-Wert fortwährend erhöhte.Übersetzung aus Ophthalmologica 2014;232:57-63 (DOI: 10.1159/000360307)

Download Full-text